Sarepta Therapeutics, Inc.

SRPT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Assets
Cash & Equivalents $599.7M $122.4M $80.3M $73.6M $257.0M $187.7M $39.9M $33.6M
Accounts Receivable $29.5M $5.2M $4.0M $2.4M $3.5M $4.7M $3.6M $3.2M
Inventory $83.6M $12.8M — — — — — —
Total Current Assets $1.23B $373.5M $224.5M $247.8M $270.8M $193.9M $45.2M $37.8M
Property, Plant & Equipment $43.2M $37.8M $37.3M $38.5M $15.0M $3.4M $4.3M $2.1M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) $14.4M $8.1M $6.6M $5.9M $5.0M $4.9M $4.8M $4.0M
Total Assets $1.31B $424.1M $273.8M $295.0M $291.6M $205.0M $54.4M $46.0M
Liabilities
Accounts Payable $8.5M $29.7M $20.2M $12.4M $8.1M $7.5M $9.4M $1.3M
Total Current Liabilities $88.3M $75.4M $62.3M $36.9M $36.0M $78.9M $20.6M $45.9M
Long-Term Debt $431.1M $17.7M $26.8M $1.5M $1.6M $1.7M $1.8M $1.8M
Total Liabilities $518.7M $87.4M $83.4M $47.4M $44.4M $81.3M $23.4M $48.8M
Stockholders' Equity
Retained Earnings $-1.22B $-1.17B $-899.1M $-679.0M $-543.2M — — —
Total Stockholders' Equity $789.2M $336.7M $190.3M $247.7M $247.2M $123.7M $31.0M $-2.8M
← Newer Page 2 of 2 Older →